Along with the benefit of compliance with state regulations to prevent controlled-substance abuse, ePrescribing can improve clinical care and efficiency.
California-licensed pharmacists, dentists and others who dispense controlled substances must follow revised reporting requirements beginning Jan. 1, 2022. Those requirements are different than the requirements for prescribing or administering controlled substances.
California dentists, physicians and other specified licensees who renew their license beginning in April 2021 will see an increase in the regulatory fee assessed annually to cover the “reasonable costs” associated with operating and maintaining CURES 2.0 ― California’s prescription drug monitoring database.
Many bills were introduced over the past year to combat the opioid epidemic in California, as CDA previously reported. Here is an overview of CDA-supported legislation in the areas of e-prescribing, informed consent, interstate data sharing and prescription-pad requirements, that Gov. Jerry Brown signed into law in September and how these bills will affect the practice of dentistry.
Beginning Oct. 2, all licensees authorized to prescribe, order, administer, furnish or dispense controlled substances in California must, with some exceptions, check a patient’s prescription history in CURES 2.0 before prescribing a Schedule II-IV substance, as CDA first reported in April. One notable exemption to mandatory CURES consultation that applies to dental care and that CDA helped secure is summarized here.
The Department of Justice on April 2 announced that California’s Controlled Substance Utilization Review and Evaluation System, also known as CURES 2.0, is ready for statewide use and that mandatory CURES consultation becomes effective Oct. 2, 2018. Beginning on this date, prescribers must check a patient’s prescription history in CURES 2.0 before prescribing a Schedule II-IV substance, with some exceptions.
